Lova Sun
Papers
5
Total Citations
31
H-Index
3
About
Lova Sun is a clinical researcher whose work focuses on optimizing treatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), particularly through the use of transoral robotic surgery (TORS) and trimodality therapy. Her major contributions center on demonstrating that definitive tumor-directed therapy can confer a survival advantage in patients with metachronous oligometastatic HPV+ oropharyngeal cancer following TORS, a finding with over 16 citations. She has also systematically evaluated functional outcomes, showing that trimodality therapy—combining TORS with adjuvant chemoradiotherapy—can achieve favorable swallowing and feeding-tube outcomes in high-risk patients. Her work on survival and toxicity profiles in this population, cited 5 times, challenges the notion that trimodality therapy inevitably leads to high toxicity, providing evidence for its safe application. Additionally, her recent research on HPV+ oropharyngeal carcinoma of unknown primary highlights the diagnostic and therapeutic utility of TORS in this rare presentation. Sun’s studies collectively advance personalized, de-escalation strategies for HPV-driven head and neck cancers, balancing oncologic efficacy with quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5